Manel Puig-Domingo
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Implicación de la Función Tiroidea Materna en la Programación Metabólica Fetal.
Open Date: 2019-01-01
Close Date: 2021-12-01
Grant: Close
Grup de recerca en endocrinologia clínica i experimental (ENDOGRUP)
Open Date: 2017-01-01
Close Date: 2020-12-01
Grant: Close
Improved and efficient therapy of acromegaly by implementation of a personalized and predictive algorithm including functional analysis, imaging and genomic information.
Open Date: 2016-12-01
Close Date: 2019-01-01
Grant: Close
Formulación de un score personalizado de predicción de riesgo fetal y obstétrico basado en la función tiroidea materna.
Open Date: 2016-01-01
Close Date: 2018-12-01
Grant: Close
Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe
Open Date: 2015-06-01
Close Date: 2018-06-01
Articles (13)
Severe hypertriglyceridemia (HTG) during pregnancy is a rare but serious condition associated with an increased risk of maternal and fetal complications. We report the case of a 36-year-old woman diagnosed with severe HTG at 28 weeks of gestation, with triglyceride (TG) levels of 2184 mg/dL (SI: 24.68 mmol/L) (reference range, 26.50-150 mg/dL [SI: 0.30-1.69 mmol/L]). Despite dietary intervention and ω-3 supplementation, levels continued to rise, requiring hospitalization and treatment with intravenous insulin. Due to refractory HTG, plasmapheresis was initiated at 33 weeks, with significant lipid reduction. At 34 weeks, the patient underwent an emergency cesarean delivery due to preterm labor. This case underscores the challenges of managing severe HTG in pregnancy and highlights the importance of early, multidisciplinary intervention. Further research is needed to refine treatment strategies and establish standardized guidelines for this high-risk population.
Year:
2025
Context Persistent hypoglycemia is a life-threatening complication in insulinoma patients. When tumor excision is not possible, medical treatments are the main option. Pasireotide has shown promise in managing refractory hypoglycemia, but its use has been reported only in case series and reports. Objective This work aimed to assess the efficacy and safety of pasireotide in treating insulinoma-associated hypoglycemia. Methods We conducted a systematic review on using pasireotide to treat insulinoma-associated hypoglycemia, following a predeveloped protocol. We searched MEDLINE, Scopus, Google Scholar, and references forward and backward from database inception to March 30, 2024. Results Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria. Patients' ages ranged from 52 to 71 years (9 women). Five patients (30%) underwent surgical tumor resection. Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3). Conclusion Pasireotide effectively restored glucose levels in insulinoma patients who failed prior treatments. However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.
Year:
2025
Objective Longitudinal evaluation of thyroid function throughout pregnancy in the same subject could offer precise information about its dynamics as a physiological mechanism of adaption to the requirements. In this study, we evaluated longitudinal trajectories of maternal thyroid function during pregnancy by a latent class growth analysis and explored their association with maternal–fetal outcomes. Methods A prospective observational study was carried out, including 414 healthy pregnant women, from the first trimester to delivery. Thyroid function and autoimmunity were measured in the three trimesters. Clinical data during pregnancy were obtained. Longitudinal mixed model techniques were performed to explore trajectories of gestational thyroid function. Results Three different longitudinal trajectories were obtained from maternal thyrotropin (TSH) levels: low-increasing TSH (class 1) in 86% of cases, high-increasing TSH (class 2) in 9.7%, and decreasing TSH (class 3) in 4.3%. No statistical differences in free thyroxine levels were found among the three classes. Differences in maternal age ( P = 0.027) and initial maternal weight ( P = 0.043) were observed among the groups. In logistic regression analysis, maternal age correlated with longitudinal trajectories. The three longitudinal classes remain when women with thyroid autoimmunity (TAI) are excluded. Multinomial logistic regression showed maternal age correlated with longitudinal trajectories independently of TAI status. Conclusions Three differentiated TSH trajectories were found in healthy pregnant women living in Catalonia, as previously described. No association with obstetric outcomes was observed in these different chronological thyroid pathways, but maternal age might condition the longitudinal mechanism of thyroid function regulation throughout pregnancy.
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (3)
Betina Biagetti
-
Mónica Marazuela
Universidad Autónoma de Madrid
Marta Araujo Castro
HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL
Make your next move.
Prepare your application
Review drafts before you send them.